Core Insights - The global growth factor drug market is steadily increasing, projected to grow from 13.2 billion in 2018 to 15.9 billion by 2025, with a compound annual growth rate (CAGR) of 3.4% [8][9] - The Chinese growth factor drug market is recovering, expected to reach 7.1 billion by 2025, doubling from 2020 levels, driven by the introduction of more human-derived products and expanded indications [9][10] - The market is characterized by a diverse range of growth factor products, with FGF holding the largest market share, followed by EGF and NGF [10] Growth Factor Drug Industry Overview - Growth factors are bioactive substances that regulate cell proliferation, migration, survival, and differentiation during tissue repair by binding to specific receptors on cell membranes [2][3] - They operate through paracrine and endocrine mechanisms, influencing local and systemic physiological processes [2][6] Market Status - The global growth factor drug market is expected to exceed 20 billion by 2029, indicating a robust growth trajectory [8] - In China, the market experienced a decline from 2019 to 2020 due to concerns over non-human-derived products and stricter regulations, but is now on a recovery path [9][10] Product Approval Status - As of December 2025, 38 growth factor drugs are expected to be approved in China, with significant contributions from companies like Zhuhai Yisheng Biopharmaceutical and Beijing Shuanglu Pharmaceutical [10][11] Development Trends - The growth factor drug market is anticipated to grow due to increasing demand for treatments in open wound care, ophthalmic diseases, and nerve regeneration [11] - Expanding indications and supportive policies are expected to accelerate new drug development and approval processes [11]
研判2025！全球及中国生长因子药物行业市场规模、市场结构、获批产品及未来趋势研判：中国市场规模增长至71亿元，FGF药物为主要产品类型[图]